Identification of people with heterozygous familial hypercholesterolemia

被引:49
|
作者
Haase, Annie [1 ]
Goldberg, Anne C. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA
基金
美国国家卫生研究院;
关键词
cascade screening; familial hypercholesterolemia; genetic testing; universal screening; ASSOCIATION EXPERT PANEL; CHOLESTEROL-LOWERING TREATMENT; RECOMMENDATIONS; DIAGNOSIS; MANAGEMENT; CHILDREN; ADULTS; HEALTH;
D O I
10.1097/MOL.0b013e3283556c33
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose of review Familial hypercholesterolemia is an underdiagnosed autosomal codominant genetic condition associated with significantly increased risk of early cardiovascular disease when untreated. Early diagnosis and treatment decrease the excess risk, and strategies for identification of affected individuals are being developed worldwide. This review will discuss, from a clinician's perspective, some of the issues involved in identifying people with familial hypercholesterolemia. Recent findings Several sets of recommendations have been published outlining the strategies for identification of people with familial hypercholesterolemia in various countries and regions. These include Australasia, Europe, and the USA. Summary Continuing efforts to find the best methods for identification of people with familial hypercholesterolemia are needed to ensure that this very treatable inherited condition is diagnosed early enough to prevent the development of atherosclerotic vascular disease.
引用
收藏
页码:282 / 289
页数:8
相关论文
共 50 条
  • [41] Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia Reply
    Gaudet, Daniel
    Ruzza, Andrea
    Santos, Raul D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (01): : 84 - 85
  • [42] ENDOTHELIUM FUNCTION IN CHILDREN WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Slastnikova, E. S.
    Sadykova, D. I.
    Galimova, L. F.
    Khaliullina, C. D.
    ATHEROSCLEROSIS, 2022, 355 : E83 - E83
  • [43] Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia
    Baum, Seth J.
    Soifer, Daniel
    Duell, P. Barton
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2016, 17 (1-2) : 17 - 25
  • [44] Colesevelam: In pediatric patients with heterozygous familial hypercholesterolemia
    Perry C.M.
    Pediatric Drugs, 2010, 12 (2) : 133 - 140
  • [45] ABNORMALITIES OF LIPOPROTEIN METABOLISM IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    JANUS, ED
    NICOLL, AM
    TURNER, PR
    WOOTTON, R
    LEWIS, B
    PATHOLOGY, 1980, 12 (01) : 140 - 140
  • [46] Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome
    Rosenson, Robert S.
    Najera, Sherwin D.
    Hegele, Robert A.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (01) : 294 - 296
  • [47] Heterozygous familial hypercholesterolemia: Diagnosis and drug therapy
    Malyshev, PP
    KARDIOLOGIYA, 2000, 40 (10) : 63 - 69
  • [48] Peripheral arterial disease in heterozygous familial hypercholesterolemia
    Pereira, Carolina
    Miname, Marcio H.
    Makdisse, Marcia R. P.
    Watanabe, Carolina
    Pesaro, Antonio E.
    Jannes, Cinthia E.
    Kalil Filho, Roberto
    Pereira, Alexandre C.
    Santos, Raul D.
    ATHEROSCLEROSIS, 2015, 242 (01) : 174 - 178
  • [49] PORTACAVAL-SHUNT FOR FAMILIAL HETEROZYGOUS HYPERCHOLESTEROLEMIA
    MADRAS, PN
    SURGERY GYNECOLOGY & OBSTETRICS, 1981, 152 (02): : 187 - 190
  • [50] PREDICTORS OF CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ACCORDING THE RUSSIAN FAMILIAL HYPERCHOLESTEROLEMIA REGISTRY
    Bliznyuk, S. A.
    Rozhkova, T. A.
    Ezhov, M. V.
    Tripoten, M. I.
    Pogorelova, O. A.
    Chubykina, U. V.
    Tmoyan, N. A.
    Balakhonova, T. V.
    Afanasieva, M. I.
    Afanasieva, O. I.
    Pokrovsky, S. N.
    ATHEROSCLEROSIS, 2020, 315 : E193 - E193